Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
ACHN - Achillion Pharmaceuticals Inc
Achillion Pharmaceuticals, Inc., incorporated on August 17, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the Company concentrates on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Achillion Pharmaceuticals Inc News
Post-Market & Company News: Updates on FB, JPM, BBY, GOOG, RDN, .INX
ValueWalk - 6 hours ago
ValueWalk - 6 hours ago
By Abhijit Sen US markets jump higher: US markets recorded the best trading session of the month on Monday as investors picked up beaten-down stocks.
Hot Stocks Of The Day (ACHN, CBE, SVU, TDW, JMBA)
The Markets Are Open (blog) - 10 hours ago
The Markets Are Open (blog) - 10 hours ago
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares gained 10.15% to $7.16 in the morning hour after the company reported proof-of-concept data from a Phase 1b clinical trial demonstrating that patients with chronic hepatitis C (HCV) genotype 1 (GT 1) ...
Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the ...
MarketWatch (press release) - 16 hours ago
MarketWatch (press release) - 16 hours ago
NEW HAVEN, Conn., May 21, 2012 (GlobeNewswire via COMTEX) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today reported proof-of-concept data from a Phase 1b clinical trial demonstrating that patients with chronic hepatitis C (HCV) genotype 1 (GT 1) ...
Achillion Announces Executive Promotion
Review seeker (press release) - May 19, 2012
Review seeker (press release) - May 19, 2012
By Globenewswire NEW HAVEN, Conn., May 18, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the ...
Achillion Announces Executive Promotion
MarketWatch (press release) - May 18, 2012
MarketWatch (press release) - May 18, 2012
NEW HAVEN, Conn., May 18, 2012 (GlobeNewswire via COMTEX) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the ...
Sunesis Pharmaceuticals Jumps On Earnings (PSTI, ACHN, SNSS, AMLN, ZGNX)
Gaining Green - May 15, 2012
Gaining Green - May 15, 2012
By Gaining Green Staff Pluristem Therapeutics Inc (NASDAQ: PSTI) surged up 3.12% to $2.94. The Company announced that cardiac function in a diabetic-induced diastolic dysfunction in animals improved following PLacental eXpanded administration.
US HOT STOCKS: Groupon, Avon Products, Agilent, Saks
Wall Street Journal - May 15, 2012
Wall Street Journal - May 15, 2012
US stocks rose slightly Tuesday as the Dow Jones Industrial Average recently added 11 points to 12706, the Standard & Poor's 500-stock index rose 1.4 points to 1340 and the Nasdaq Composite gained 8.7 points to 2911.
US STOCK FUTURES: HOT STOCKS TO WATCH
Wall Street Journal - May 15, 2012
Wall Street Journal - May 15, 2012
Among the companies with shares expected to actively trade in Tuesday's session are Groupon Inc. (GRPN), Avon Products Inc. (AVP) and Agilent Technologies Inc. (A).
Pre Market Winners and Losers for May 15: OREX, RENN, ACHN, MM, LOW
Active Investor - May 15, 2012
Active Investor - May 15, 2012
Orexigen Therapeutics, Inc. (NASDAQ:OREX) is up 5.08% in pre market trading at $4.14. OREX is seeing light volume this morning with 2 thousand shares traded.
Achillion Gets Fast Track Designation For ACH-3102 To Treat Chronic Hepatitis C
RTT News - May 15, 2012
RTT News - May 15, 2012
(RTTNews) - Achillion Pharmaceuticals, Inc. (ACHN: News ) announced the receipt of a fast track designation from the US Food and Drug Administration, or FDA, for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C, ...
ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of ... - GlobeNewsWire (press release) NYSE Media Coverage Selection of the best articles found in your favorit medias